Skip to main content
SpringerLink
Log in

Follicular lymphoma international prognostic index

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Although numerous treatment approaches are proposed for patients with follicular lymphoma, criteria to help in choosing a treatment for a given patient and for comparing trial results are lacking. Several retrospective studies have analyzed prognostic factors, but their conclusions rely on limited numbers of patients treated during long periods, and their results are discordant. The Follicular Lymphoma International Prognostic Index was designed from the data recorded over 8 years of nearly 5000 patients registered worldwide. Five factors are used (age, Ann Arbor stage, number of nodal sites, serum lactate dehydrogenase level, and hemoglobin level) to build a threecategory index. This index, together with new biologic markers such as gene profiling and proteomics, could help provide an optimal treatment option for patients with follicular lymphoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Morton LM, Wang SS, Devesa SS, et al.: Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006, 107:265–276. This paper reports a large epidemiologic study of all NHL subtypes in a cohort of more than 10,000 patients and shows the pattern variations during recent years.

    Article  PubMed  CAS  Google Scholar 

  2. McLaughlin P, Grillo-Lopez AJ, Link BK, et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825–2833. This paper reports the results of the pivotal study of rituximab in low-grade (most of them follicular) non-Hodgkin's lymphomas. The response rate was 50%, with a median time to treatment failure of 12 months in this heavily pretreated population of patients.

    PubMed  CAS  Google Scholar 

  3. Solal-Celigny P: Prognosis of follicular lymphomas. Clin Lymphoma 2005, 6:21–25.

    Article  PubMed  Google Scholar 

  4. Solal-Celigny P, Roy P, Colombat P, et al.: Follicular lymphoma international prognostic index. Blood 2004, 104:1258–1265. Original paper describing the FLIPI and detailing the steps leading to the elaboration of this index and its validation.

    Article  PubMed  CAS  Google Scholar 

  5. Perea G, Altes A, Montoto S, et al.: Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems. Ann Oncol 2005, 16:1508–1513.

    Article  PubMed  CAS  Google Scholar 

  6. Arcaini L, Colombo N, Passamonti F, et al.: Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment. Leuk Res 2006, 30:277–282.

    Article  PubMed  Google Scholar 

  7. Colocci N, Weller E, Hochster HS, et al.: Prognostic significance of the follicular lymphoma international prognostic index (FLIPI) in the E1496 trial of chemotherapy with or without maintenance rituximab [abstract 6526]. J Clin Oncol 2005, 23:566s.

    Google Scholar 

  8. Imrie K, Belch A, Pettengell R, et al.: Rituximab plus CVP chemotherapy vs. CVP alone as first-line treatment for follicular lymphoma: treatment effect according to baseline prognostic factors [abstract 6525]. J Clin Oncol 2005, 23:566s.

    Google Scholar 

  9. Kaminski MS, Coleman M, Lunk BK, et al.: Tositumomab and iodine I 131 tositumomab: efficacy and safety in 141 patients (pts) with previously untreated low-grade (LG) non-Hodgkin's lymphoma. J Clin Oncol 2005, 23:525s.

    Article  CAS  Google Scholar 

  10. Montoto S, Lopez-Guillermo A, Altes A, et al.: Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression. Ann Oncol 2004, 15:1484–1489.

    Article  PubMed  CAS  Google Scholar 

  11. Wilder RB, Jones D, Tucker SL, et al.: Long-term results with radiotherapy for stage I-II follicular lymphomas. Int J Radiat Oncol Biol Phys 2001, 51:1219–1227.

    Article  PubMed  CAS  Google Scholar 

  12. Colombat P, Salles G, Brousse N, et al.: Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001, 97:101–106.

    Article  PubMed  CAS  Google Scholar 

  13. Ghielmini M, Schmitz SF, Cogliatti SB, et al.: Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004, 103:4416–4423. In this paper, a maintenance treatment with rituximab (375 mg/m2 every 2 months) improved the median progression-free survival of patients who had initially responded to a conventional four weekly doses of rituximab.

    Article  PubMed  CAS  Google Scholar 

  14. Marcus R, Imrie K, Belch A, et al.: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005, 105:1417–1423.

    Article  PubMed  CAS  Google Scholar 

  15. Hiddemann W, Kneba M, Dreyling M, et al.: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005, 106:3725–3732.

    Article  PubMed  CAS  Google Scholar 

  16. Czuczman MS, Weaver R, Alkuzweny B, et al.: Prolonged clinical and molecular remission in patients with lowgrade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004, 22:4711–4716.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre Jean Bernard, 9 rue Beauverger, 72000, Le Mans, France

    Philippe Solal-Celigny MD, PhD

Authors
  1. Philippe Solal-Celigny MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Solal-Celigny, P. Follicular lymphoma international prognostic index. Curr. Treat. Options in Oncol. 7, 270–275 (2006). https://doi.org/10.1007/s11864-006-0036-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-006-0036-3

Keywords

Search

Navigation